Established medications combat lung cancer tumor growth
Share

IMAGE: A representation of the EGFR protein, which plays a role in the progression of lung tumors driven by mutations in the KRAS protein. This material relates to a paper that… view more 

Credit: biolution GmbH 2018

Two research groups have discovered that the growth of an intractable type of lung cancer in mouse models can be restrained with a class of drug known as kinase inhibitors. Both studies also identified FDA-approved kinase inhibitors that successfully curtailed lung tumor growth in several mouse models, pointing to new therapeutic avenues for a form of lung cancer that currently has few effective treatments. Lung cancer is the deadliest form of cancer in both men and women, accounting for more than 1.5 million deaths each year around the world. One third of lung adenocarcinomas – one of the most common lung cancer types – are associated with mutations in the KRAS gene. This gene codes for a protein that normally regulates the growth and division of cells, but when it is mutated it can promote uncontrollable cell growth and tumor formation in a way that is assumed to be resistant to kinase inhibition. Despite extensive research, there are no existing therapies that

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD